Nasdaq , ARNA
Arena Pharmaceuticals, Inc. is a bio-pharmaceutical company with a pipeline of internally discovered, small-molecule product candidates that target G protein-coupled receptors. Arena Pharmaceuticals’ product candidates act on or through known and orphan GPCRs, and have been discovered using Arena Pharmaceuticals’ own GPCR-focused drug discovery technologies and capabilities. Two of the company’s product candidates are in clinical trials. APD356, being developed for the treatment of obesity, is in a phase II clinical trial. APD125, being developed for the treatment of insomnia, is in a phase I clinical trial. Arena Pharmaceuticals also has active collaborations with two pharmaceutical companies for the development of compounds targeted for the treatment of type 2 diabetes, and atherosclerosis and related disorders. These collaborative partners are Ortho-McNeil Pharmaceutical, Inc. and Merck & Co., Inc.
Total number of shares outstanding as of Sept. 9 35,300,000
Price of each share of common stock on Sept. 9 $9.20
Aggregate market value as of Sept. 9 $324,760,000
For year ended Dec. 31.
2004 2003 2002
Total revenues $13,685,822 $12,834,279 $19,421,765
Net income (loss) ($57,991,770) ($47,059,439) ($32,829,938)
Net income (loss) per share ($2.40) ($1.74) ($1.19)
Total assets $206,364,995 $229,898,109 $254,890,047
Jack Lief, 59, director since 1997.
Dominic Behan, 41, director since 2000.
Donald Belcher, 66, director since 2003.
Scott Bice, 62, director since 2003.
Harry Hixson Jr., 66, director since 2004.
J. Clayburn La Force Jr., 76, director since 2002.
Louis J. Lavigne Jr., 56, director since 2005.
Tina Nova, 51, director since 2004.
Officer 2004 Cash Compensation
Jack Lief, president and chief executive officer $653,750
Dominic Behan, senior vice president and chief scientific officer $370,000
Steven Spector, senior vice president, general counsel and secretary $335,000
William Shanahan Jr., vice president and chief medical officer $269,125
Louis Scotti, vice president, marketing and business development $241,000
Significant Stock Ownership
Number of shares Percent
Perry Capital LLC 2,806,154 8
Mainfield Enterprises, Inc. 2,805,765 8
Smithfield Fiduciary LLC 2,104,324 6
Dimensional Fund Advisors Inc. 2,019,932 5.7
TCW Business Unit 1,959,129 5.6
Directors and officers as a group (15 people) 2,750,085 7.4
Headquarters: 6166 Nancy Ridge Drive, San Diego, CA 92121; (858) 453-7200; fax (858) 453-7210.
Web site: www.arenapharm.com.
Auditors: Ernst & Young LLP.
Industry: Drug manufacturers.
Information was compiled from the company’s annual and proxy reports.